Literature DB >> 16983183

Audiometric patterns in ototoxicity of intra-arterial Cisplatin chemoradiation in patients with locally advanced head and neck cancer.

C L Zuur1, Y J W Simis, P E M Lansdaal, C R N Rasch, R A Tange, A J M Balm, W A Dreschler.   

Abstract

This study describes audiometric patterns of ototoxicity in a consecutive series of patients uniformly treated with intra-arterial high-dose cisplatin chemoirradiation for advanced cancer of the head and neck. Air conduction thresholds were measured from 0.125 to 16 kHz and bone conduction thresholds were measured from 0.5 to 4 kHz. The overall audiometric pattern was characterized by maximum threshold shifts after the 2nd cisplatin infusion and a maximum total threshold shift at 8 kHz, irrespective of gender, age, pretreatment sensorineural hearing loss (SNHL) or subjective complaints during therapy. A hearing deterioration gradient was observed from (ultra-) high to low frequencies, worse with increasing pre-existent SNHL and with increasing cumulative dose of cisplatin chemoradiation. Cisplatin chemoradiation-induced hearing loss seemed to reach a plateau at higher levels (75-80 dB HL) for frequencies above 8 kHz compared to frequencies up to 8 kHz (45-60 dB HL). Recovery of SNHL was found after therapy in 27 ears characterized by extensive hearing loss at frequencies 1, 2 and 4 kHz. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16983183     DOI: 10.1159/000095818

Source DB:  PubMed          Journal:  Audiol Neurootol        ISSN: 1420-3030            Impact factor:   1.854


  8 in total

1.  Is routine audiometric evaluation necessary in gynaecologic tumour patients undergoing chemotherapy?

Authors:  Ayotunde J Fasunla; Nadia Harbeck; Barbara Schmalfeld; Sabina Berktold; Christina Böhner; Walter Hundt; Petra Wolf; Silke Steinbach
Journal:  Breast Care (Basel)       Date:  2013-08       Impact factor: 2.860

2.  Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients.

Authors:  Allison Yancey; Michael S Harris; Akinbode Egbelakin; Jaimie Gilbert; David B Pisoni; Jamie Renbarger
Journal:  Pediatr Blood Cancer       Date:  2012-03-19       Impact factor: 3.167

3.  Hearing and tinnitus in head and neck cancer patients after chemoradiotherapy.

Authors:  Riina Niemensivu; K Saarilahti; J Ylikoski; A Aarnisalo; A A Mäkitie
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-12-21       Impact factor: 2.503

Review 4.  Cisplatin ototoxicity and protection: clinical and experimental studies.

Authors:  Leonard P Rybak; Debashree Mukherjea; Sarvesh Jajoo; Vickram Ramkumar
Journal:  Tohoku J Exp Med       Date:  2009-11       Impact factor: 1.848

Review 5.  Prevention and restoration of hearing loss associated with the use of cisplatin.

Authors:  Felician Chirtes; Silviu Albu
Journal:  Biomed Res Int       Date:  2014-07-22       Impact factor: 3.411

6.  Ototoxicity and Platinum Uptake Following Cyclic Administration of Platinum-Based Chemotherapeutic Agents.

Authors:  Benjamin K Gersten; Tracy S Fitzgerald; Katharine A Fernandez; Lisa L Cunningham
Journal:  J Assoc Res Otolaryngol       Date:  2020-06-24

Review 7.  Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies.

Authors:  Angela Callejo; Lara Sedó-Cabezón; Ivan Domènech Juan; Jordi Llorens
Journal:  Toxics       Date:  2015-07-15

8.  Report on hearing loss in oncology.

Authors:  Christiane Schultz; Maria Valéria Schmidt Goffi-Gomez; Patrícia Helena Pecora Liberman; André Lopes Carvalho
Journal:  Braz J Otorhinolaryngol       Date:  2009 Sep-Oct
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.